SCHEMBL23948699

SCHEMBL23948699

CCCNC(C)(C)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.57
CYP2D6 P10635 2/20 0.40
HTR1A P08908 1/20 0.40
SCN1A P35498 1/20 0.40
SLC6A3 Q01959 1/20 0.40
SCN5A Q14524 1/20 0.40
SCN2A Q99250 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SCN3A Q9NY46 1/20 0.40
TSHR P16473 2/20 0.35
ALDH1A1 P00352 2/20 0.35
ALOX15 P16050 1/20 0.33
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
MMP1 P03956 1/20 0.33
MMP2 P08253 1/20 0.33
MMP3 P08254 1/20 0.33
MMP9 P14780 1/20 0.33
EPHX1 P07099 2/20 0.32
CTSD P07339 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28370224 0.86 KDM4C (0.48) KDM4CALOX15MMP2EPHX1HDAC3
SCHEMBL3885213 0.84 KDM4C (0.47) KDM4CTDP1TSHRALDH1A1ALOX15
SCHEMBL29437846 0.82 EPHX1 (0.48) KDM4CTDP1TSHRALDH1A1ALOX15
SCHEMBL30812349 0.82 EPHX1 (0.48) KDM4CTDP1TSHRALDH1A1ALOX15
SCHEMBL3856282 0.82 EPHX1 (0.48) KDM4CTDP1TSHRALDH1A1ALOX15
SCHEMBL3850619 0.82 EPHX1 (0.48) KDM4CTDP1TSHRALDH1A1ALOX15
SCHEMBL6889519 0.82 EPHX1 (0.48) KDM4CTDP1TSHRALDH1A1ALOX15
SCHEMBL30255194 0.82 EPHX1 (0.48) KDM4CTDP1TSHRALDH1A1ALOX15
Hydrochloric Acid SCHEMBL11673567 0.81 EPHX1 (0.47) KDM4CTDP1TSHRALDH1A1ALOX15
SCHEMBL2555427 0.80 KDM4C (0.42) KDM4CCYP2D6TDP1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-02 US disclosed
CN-114630835-B Process for the preparation of peptide compounds comprising sterically bulky amino acids 中外制药株式会社 2025-02-11 CN disclosed
US-12195700-B2 Liquid detergent having low viscosity AJINOMOTO CO., INC. (JP) 2025-01-14 US disclosed
US-20230060024-A1 RESIN COMPOSITION AND METHOD FOR PRODUCING MOLDED ARTICLES SEKISUI CHEMICAL CO., LTD. (JP) 2023-02-23 US disclosed
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-26 US disclosed
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-01-26 US disclosed
EP-4101624-A1 RESIN COMPOSITION AND METHOD FOR PRODUCING MOLDED ARTICLES SEKISUI CHEMICAL CO., LTD. (JP) 2022-12-14 EP disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-4056580-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-14 EP disclosed
CN-114630835-A Process for the preparation of peptide compounds comprising sterically bulky amino acids 中外制药株式会社 2022-06-14 CN disclosed
EP-3904357-A1 SPIRO COMPOUND AND MEDICAL USES THEREOF The National Institutes of Pharmaceutical R&D Co., Ltd (CN) 2021-11-03 EP disclosed
US-20210323922-A1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES, INC. (US) 2021-10-21 US disclosed
CN-110938095-A Novel tenofovir mixed ester-amide prodrug 正大天晴药业集团股份有限公司 2020-03-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323922-A1 PD-1/PD-L1 INHIBITORS CD274, PDCD1, PDCD1LG2 KDM4C 1528/4885CYP2D6 1713/4885HTR1A 3534/4885
US-20230026641-A1 METHOD FOR PRODUCING PEPTIDE COMPOUND COMPRISING HIGHLY STERICALLY HINDERED AMINO ACID DNPEP, VIP, NPEPPS KDM4C 4665/4885CYP2D6 4794/4885HTR1A 2917/4885
US-12404299-B2 Method for producing peptide compound comprising highly sterically hindered amino acid DNPEP, VIP, NPEPPS KDM4C 4665/4885CYP2D6 4794/4885HTR1A 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.